Bioceres Crop Solutions Price Target Adjusted by Lake Street Capital

Bioceres Crop Solutions (NASDAQ:BIOX) has recently seen its price target adjusted by Lake Street Capital. In a research report released on Friday, analysts at Lake Street Capital lowered their price objective for the company from $13.00 to $8.00. Despite this reduction, the firm continues to maintain a "buy" rating on the stock.

The new price target of $8.00 implies a potential upside of 44.14% based on the stock’s previous closing price. This estimate suggests that investors could see significant gains if the stock performs well in the upcoming period.

Other Analyst Ratings

In addition to Lake Street Capital, various other research analysts have also provided their insights on Bioceres Crop Solutions. Oppenheimer recently decreased their price target from $13.00 to $12.00 while maintaining an "outperform" rating. Meanwhile, Canaccord Genuity Group lowered their price objective from $9.50 to $7.00 and also set a "buy" recommendation for the company.

Overall, the stock has received a consensus rating of "Buy" from multiple analysts, with a current average price target of $10.00 according to data from MarketBeat. Notably, four analysts rate the stock as a buy, and two analysts have given it a strong buy rating.

Bioceres Crop Solutions – Stock Performance Overview

On the day of the report, shares of BIOX were trading down by $0.03, settling at $5.55 during Friday’s trading. The trading volume reached 674,980 shares, which exceeded the average volume of 239,543 shares for the stock. Bioceres Crop Solutions has a market capitalization of approximately $348.04 million.

The company’s stock has experienced notable fluctuations, with a twelve-month low of $5.50 and a high of $14.05. Furthermore, the firm carries a PE ratio of 277.64, reflecting its current earnings scenario. Financial ratios indicate a debt-to-equity ratio of 0.37, a current ratio of 1.27, and a quick ratio of 0.87, showcasing its financial stability and liquidity.

Recent Earnings Announcements

Bioceres Crop Solutions reported its quarterly earnings results on November 11, where it revealed an earnings per share (EPS) of ($0.09). This result fell short of the consensus estimate of $0.02 EPS by 11 cents. Revenue for the quarter stood at $92.60 million, which was below analyst expectations of $117.15 million. In terms of performance, Bioceres reported a net margin of 0.53% and a return on equity of 0.68%. Comparatively, during the same quarter the previous year, the reported EPS was ($0.07).

Institutional Investor Activity

In terms of institutional investment, a number of hedge funds have been active in buying and selling shares of BIOX. For instance, Dimensional Fund Advisors LP boosted its shareholding by 9.5% in the second quarter. Meanwhile, Fourth Sail Capital LP significantly increased its stake by 61.6% during the third quarter. Stifel Financial Corp and JPMorgan Chase & Co. also raised their holdings in Bioceres, contributing to a notable percentage of stock ownership by institutional investors which currently stands at around 17.68%.

Company Overview

Bioceres Crop Solutions Corp. is actively engaged in providing solutions that enhance crop productivity. The company operates across different segments, including Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment focuses on delivering seed traits, germplasms, and treatment packs designed to foster healthier and higher-yielding crops.

Bioceres, Investment, Analysts